Long-term outcome after bone marrow transplantation for severe aplastic anemia

被引:145
作者
Ades, L
Mary, JY
Robin, M
Ferry, C
Porcher, R
Esperou, H
Ribaud, P
Devergie, A
Traineau, R
Gluckman, E
Socié, G
机构
[1] Hop St Louis, Hematol Serv Greffe Moelle, F-75475 Paris 10, France
[2] Univ Paris 07, INSERM ERM 0321, Serv Hematol Greffe Moelle, Paris, France
[3] Univ Paris 07, INSERM ERM 0220, Serv Hematol Greffe Moelle, Paris, France
关键词
D O I
10.1182/blood-2003-07-2546
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
From January 1978 to December 2001, 133 patients with severe aplastic anemia (SAA) underwent non-T cell-depleted allogeneic bone marrow transplantation from an HLA-identical sibling donor, at the Hospital Saint Louis using either the combination of cyclophosphamide (Cy) and thoracoabdominal irradiation (TAI; n = 100) or Cy and antithymocyte globulin (ATG; n = 33), as a conditioning regimen. With 13.6 years of follow-up, the 10-year survival estimate was 64%. Four factors were associated with lower survival: older age, use of Cy-TAI, any form of treatment prior to transplantation (either androgens or immunosuppressive therapy, (IST]), and grade II to IV acute graft-versus-host disease (GvHD). TAI was the sole factor associated with the occurrence of acute GvHD. The risk of cancers (15-year cumulative incidence, 10.9%) was associated with older age and with the use of cyclosporine as IST before transplantation. Cumulative incidences and risk factors of nonmalignant late effect including avascular osteonecrosis and late bacterial, viral, and fungal infection were also analyzed. Improved results using Cy-ATG as conditioning can lead to more than 90% chance of cure in patients with SAX Even if, in our experience, the role of Cy-ATG versus that of Cy-TAI remained inextricably related to the year of transplantation, the major detrimental role of the GvHD disease in the long-term outcome and its relation to TAI supports avoidance of irradiation in the conditioning regimen. Furthermore, avoidance of any IST before transplantation in patients with a sibling donor is a prerequisite for attaining such excellent results. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2490 / 2497
页数:8
相关论文
共 51 条
[1]
Treatment of acquired severe aplastic anemia:: Bone marrow transplantation compared with immunosuppressive therapy -: The European Group for Blood and Marrow Transplantation Experience [J].
Bacigalupo, A ;
Brand, R ;
Oneto, R ;
Bruno, B ;
Socié, G ;
Passweg, J ;
Locasciulli, A ;
Van Lint, MT ;
Tichelli, A ;
McCann, S ;
Marsh, J ;
Ljungman, P ;
Hows, J ;
Marin, P ;
Schrezenmeier, H .
SEMINARS IN HEMATOLOGY, 2000, 37 (01) :69-80
[2]
Current results of bone marrow transplantation in patients with acquired severe aplastic anemia -: Report of the European group for blood and marrow transplantation [J].
Bacigalupo, A ;
Oneto, R ;
Bruno, B ;
Socié, G ;
Passweg, J ;
Locasciulli, A ;
Van Lint, MT ;
Tichelli, A ;
McCann, S ;
Marsh, J ;
Ljungman, P ;
Hows, J ;
Marin, P ;
Schrezenmeier, H .
ACTA HAEMATOLOGICA, 2000, 103 (01) :19-25
[3]
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients [J].
Bacigalupo, A ;
Bruno, B ;
Saracco, P ;
Di Bona, E ;
Locasciulli, A ;
Locatelli, F ;
Gabbas, A ;
Dufour, C ;
Arcese, W ;
Testi, G ;
Broccia, G ;
Carotenuto, M ;
Coser, P ;
Barbui, T ;
Leoni, P ;
Ferster, A .
BLOOD, 2000, 95 (06) :1931-1934
[4]
BACIGALUPO A, 1994, HAEMATOLOGICA, V79, P438
[5]
ANTILYMPHOCYTE GLOBULIN, CYCLOSPORINE, AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH ACQUIRED SEVERE APLASTIC-ANEMIA (SAA) - A PILOT-STUDY OF THE EBMT SAA WORKING PARTY [J].
BACIGALUPO, A ;
BROCCIA, G ;
CORDA, G ;
ARCESE, W ;
CAROTENUTO, M ;
GALLAMINI, A ;
LOCATELLI, F ;
MORI, PG ;
SARACCO, P ;
TODESCHINI, G ;
COSER, P ;
IACOPINO, P ;
VANLINT, MT ;
GLUCKMAN, E .
BLOOD, 1995, 85 (05) :1348-1353
[6]
BONE-MARROW TRANSPLANTATION (BMT) VERSUS IMMUNOSUPPRESSION FOR THE TREATMENT OF SEVERE APLASTIC-ANEMIA (SAA) - A REPORT OF THE EBMT SAA WORKING PARTY [J].
BACIGALUPO, A ;
HOWS, J ;
GLUCKMAN, E ;
NISSEN, C ;
MARSH, J ;
VANLINT, MT ;
CONGIU, M ;
DEPLANQUE, MM ;
ERNST, P ;
MCCANN, S ;
RAGAVASHAR, A ;
FRICKHOFEN, N ;
WURSCH, A ;
MARMONT, AM ;
GORDONSMITH, EC .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (02) :177-182
[7]
Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation [J].
Bittencourt, H ;
Rocha, V ;
Chevret, S ;
Socié, G ;
Espérou, H ;
Devergie, A ;
Dal Cortivo, L ;
Marolleau, JP ;
Garnier, F ;
Ribaud, P ;
Gluckman, E .
BLOOD, 2002, 99 (08) :2726-2733
[8]
GROWTH AND GROWTH-HORMONE SECRETION AFTER BONE-MARROW TRANSPLANTATION [J].
BRAUNER, R ;
FONTOURA, M ;
ZUCKER, JM ;
DEVERGIE, A ;
SOUBERBIELLE, JC ;
PREVOTSAUCET, C ;
MICHON, J ;
GLUCKMAN, E ;
GRISCELLI, C ;
FISCHER, A ;
RAPPAPORT, R .
ARCHIVES OF DISEASE IN CHILDHOOD, 1993, 68 (04) :458-463
[9]
Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation [J].
Brauner, R ;
Adan, L ;
Souberbielle, JC ;
Esperou, H ;
Michon, J ;
Devergie, A ;
Gluckman, E ;
Zucker, JM .
JOURNAL OF PEDIATRICS, 1997, 130 (05) :785-792
[10]
Cohen A, 1999, BLOOD, V93, P4109